BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33609690)

  • 41. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
    Tremblay MR; Lin SX; Poirier D
    Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
    Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
    J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical Pharmacokinetics, Tissue Distribution and Primary Safety Evaluation of a Novel Curcumin Analogue H10 Suspension, a Potential 17β Hydroxysteroid Dehydrogenase Type 3 Inhibitor.
    Xiao L; Bei Y; Li J; Chen M; Zhang Y; Xiang Q
    Chem Pharm Bull (Tokyo); 2021 Jan; 69(1):52-58. PubMed ID: 33087639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3.
    Cheng Y; Yang Y; Wu Y; Wang W; Xiao L; Zhang Y; Tang J; Huang YD; Zhang S; Xiang Q
    Front Pharmacol; 2020; 11():637. PubMed ID: 32457626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps.
    Negri M; Recanatini M; Hartmann RW
    J Comput Aided Mol Des; 2011 Sep; 25(9):795-811. PubMed ID: 21822722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of 3beta- and 17beta-hydroxysteroid dehydrogenase activities in rat Leydig cells by perfluorooctane acid.
    Zhao B; Chu Y; Hardy DO; Li XK; Ge RS
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):13-7. PubMed ID: 19818404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.
    Djigoué GB; Ngatcha BT; Roy J; Poirier D
    Molecules; 2013 Jan; 18(1):914-33. PubMed ID: 23344201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme.
    LE Lain R; Barrell KJ; Saeed GS; Nicholls PJ; Simons C; Kirby A; Smith HJ
    J Enzyme Inhib Med Chem; 2002 Apr; 17(2):93-100. PubMed ID: 12420755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
    Ajduković JJ; Djurendić EA; Petri ET; Klisurić OR; Celić AS; Sakač MN; Jakimov DS; Gaši KM
    Bioorg Med Chem; 2013 Dec; 21(23):7257-66. PubMed ID: 24148837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.